These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26227815)

  • 1. Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption.
    De Masi R; Accoto S; Orlando S; De Blasi V; Pasca S; Scarpello R; Spagnolo L; Idolo A; De Donno A
    BMC Neurol; 2015 Jul; 15():125. PubMed ID: 26227815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.
    Fragoso YD; Gama PDD; Gomes S; Khouri JMN; Matta APDC; Fernanda Mendes M; Stella CRAV
    Mult Scler Relat Disord; 2016 Mar; 6():64-65. PubMed ID: 27063625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune reconstitution inflammatory syndrome and rebound syndrome in multiple sclerosis patients who stopped disease modification therapy: current understanding and a case report].
    Belova AN; Rasteryaeva MV; Zhulina NI; Belova EM; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):74-84. PubMed ID: 28617365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
    Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
    Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
    Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
    Sánchez P; Meca-Lallana V; Vivancos J
    Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.
    Evangelopoulos ME; Koutoulidis V; Andreadou E; Evangelopoulos DS; Kilidireas C
    Int J Neurosci; 2016 Dec; 126(12):1097-102. PubMed ID: 26727713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune thrombocytopenic purpura associated with fingolimod.
    Yuen HLA; Brown S; Chan N; Grigoriadis G
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28893804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.
    Lin W; Chou CH; Yang FC; Tsai CK; Lin YK; Sung YF
    Front Immunol; 2023; 14():1115120. PubMed ID: 37122715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
    Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
    Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte recovery after fingolimod discontinuation in patients with MS.
    Nagy S; Kuhle J; Derfuss T
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
    Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
    Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia.
    Caliendo D; Grassia MC; Carotenuto A; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
    Mult Scler Relat Disord; 2024 Jan; 81():105135. PubMed ID: 38006850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.